Evaluation of the safety, efficacy and acceptability of HMR 3647 (20 percent fine granules 1g sachet) in children with infections

Trial Profile

Evaluation of the safety, efficacy and acceptability of HMR 3647 (20 percent fine granules 1g sachet) in children with infections

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Telithromycin (Primary)
  • Indications Bacterial infections; Dental infections; Otorhinolaryngological infections; Respiratory tract infections; Skin infections
  • Focus Adverse reactions; Registrational
  • Sponsors Sanofi
  • Most Recent Events

    • 08 Apr 2009 Actual end date (May 2005) added as reported by ClinicalTrials.gov.
    • 15 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top